ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 ...

More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control ...

A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.

Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell ...

The study builds on data from an early-stage study which evaluated CD19 CAR-NK cell therapy in combination with the Rituximab ...

More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS). The ...

Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPFFindings extend MiNK’s iNKT platform into chronic ...

GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026Phase 1 protocol allows multiple solid tumor types known to express ...

Recent press releases from two new partners of NextGenNK highlight important advances in natural killer (NK) cell-based immunotherapies, spanning both ...

Omisirge transplantation shows accelerated immune recovery in SAANew data presented at the 2026 TANDEM Meetings demonstrate that patients with SAA who received Omisirge experienced faster and more rob ...

Validated, tissue-specific library enables customisable and controllable liver-targeted gene expression with high specificity and minimal off-target activity in muscle tissue ...